Catalyst Pharmaceuticals (CPRX) Total Current Liabilities (2010 - 2026)

Catalyst Pharmaceuticals (CPRX) has 17 years of Total Current Liabilities data on file, last reported at $132.4 million in Q1 2026.

• Quarterly Total Current Liabilities rose 18.58% year-over-year to $132.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $132.4 million (up 18.58% YoY) and the FY2025 annual result came in at $147.2 million, up 21.94% from the prior year.
• Total Current Liabilities slipped to $132.4 million in Q1 2026, from $147.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $147.2 million in Q4 2025 to a low of $22.5 million in Q2 2022.
• A 5-year average of $83.6 million and a median of $79.6 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities jumped 147.23% — and 2026, when it climbed 18.58%.
• Tracing CPRX's Total Current Liabilities over 5 years: stood at $57.6 million in 2022, then soared by 32.08% to $76.1 million in 2023, then jumped by 58.66% to $120.7 million in 2024, then gained by 21.94% to $147.2 million in 2025, then retreated by 10.03% to $132.4 million in 2026.
• The last three Total Current Liabilities figures came in at $132.4 million (Q1 2026), $147.2 million (Q4 2025), and $128.7 million (Q3 2025), per Business Quant data.